The same hallucinogen component as magic mushroom is approved by the authorities as a `` breakthrough treatment '' for depression

by Shutterbug75

Have studied the mental health with a focus on depression and anxiety disorders Usona Institute is, ' psilocybin with major depressive disorder treatment of (MDD) is the United States Food and Drug Administration by the (FDA) epoch-making treatment I received a drug designation '.

FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder | Business Wire
https://www.businesswire.com/news/home/20191122005452/en/FDA-grants-Breakthrough-Therapy-Designation-Usona-Institutes

Exciting announcement! Usona's psilocybin program for major depression has received Breakthrough Therapy Designation from the FDA.Read more: https://t.co/M4vLUuzoeS

— Usona Institute (@usonainstitute) November 22, 2019

Psilocybin for major depression granted Breakthrough Therapy by FDA
https://newatlas.com/science/psilocybin-major-depression-mdd-usona-breakthrough-therapy-fda/

Sirocibin is a hallucinogen component contained in magic mushrooms and has been suggested by past studies to improve depression, so intractable depression (TRD) for which conventional drugs are not effective enough ) Was a limited treatment.

You can read the following article about the effects of sirocibin on depression.

It turned out that magic mushrooms may have a function to restart the brain circuit in the `` depressed '' state-GIGAZINE

by Karolynne Steen

Clinical trials found that magic mushrooms remove severe depression-gigazine

by Gregor Dodson

Following this, the FDA has now approved the use of sirocibin in a new clinical trial for major depressive disorder (MDD) . MDD is a mental illness characterized by symptoms commonly known as depression, such as depressed mood, diminished interest, cognitive impairment, sleep disorders, and appetite disorders. The degree is said to be experienced. There are also more patients than TRD, with an estimated 5 million people in the United States, compared to approximately 17 million MDD patients.

Charles Raison, director of clinical research and bridging research at Usona Laboratories, said, “Past studies have shown that sirocibin can have a significant effect on the treatment of patients with MDD. 'You can actually confirm with' In addition, “the real breakthrough was not only intractable depression with a small number of patients, but also in MDD, where many patients suffer from symptoms,” and welcomed the decision by the FDA. .

Usona Laboratories will conduct a second-stage clinical trial following the first-stage clinical trial that had been conducted with the previous approval, and will complete the clinical trial by the beginning of 2021. In the second-stage clinical trial conducted in earnest with this approval, a total of 80 people from seven medical institutions in the United States will participate, and depending on the results, a larger third-stage clinical trial The exam is expected to be conducted.